Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Dec 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ipilimumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms ANZUP2001; EVOLUTION

11 Dec 2023 Planned primary completion date changed from 1 Jun 2024 to 31 Aug 2024.
11 Dec 2023 Status changed from recruiting to active, no longer recruiting.
29 Mar 2023 Planned number of patients changed from 110 to 100, as per trial design presented at the 2023 Genitourinary Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com